13F Holdings
中文EN

DXCM DEXCOM INC

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1093557 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.0%
TTM net income YoY37.5%
TTM EPS YoY41.1%
Revenue 3-yr CAGR14.5%
Net income 3-yr CAGR38.0%

Margins

Gross margin63.4%
Operating margin24.0%
Net margin19.4%
FCF margin21.5%
EBITDA margin29.4%

Returns

ROE37.7%
ROA14.4%
ROIC (approx.)78.0%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets59.4%
Debt / equity0.00x
Current ratio1.74x
Interest coverage91.33x

Cash quality & payout

Operating cash flow / net income1.43x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue6.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.66B$4.03B$3.62B$2.91B$2.45B
Cost of revenue$1.86B$1.59B$1.33B$1.03B$768.00M
Gross profit$2.80B$2.44B$2.29B$1.88B$1.68B
R&D expense$599.10M$552.40M$505.80M$484.20M$517.10M
SG&A expense$1.29B$1.29B$1.19B$1.01B$810.50M
Operating income$911.80M$600.00M$597.70M$391.20M$265.80M
Interest expense$18.30M$19.00M$20.30M$18.60M$18.80M
Pretax income$1.09B$709.00M$710.40M$390.80M$256.80M
Income tax$252.10M$132.80M$168.90M$49.60M$39.90M
Net income$836.30M$576.20M$541.50M$341.20M$216.90M
EBITDA$1.16B$817.70M$783.70M$547.10M$367.80M
EPS (basic)2.141.461.400.880.56
EPS (diluted)2.091.421.300.820.53
Weighted avg. shares (diluted)405.50M412.70M425.50M427.50M428.80M
Balance sheet
Cash & equivalents$917.70M$607.30M$566.30M$643.30M$1.05B
Short-term investments—$1.73B$2.16B$1.81B$1.36B
Receivables$1.22B$1.01B$973.90M$713.30M$514.30M
Inventory$629.10M$542.60M$559.60M$306.70M$357.30M
Current assets$4.03B$4.30B$4.43B$3.67B$3.68B
PP&E, net$1.56B$1.34B$1.11B$1.06B$801.80M
Goodwill$24.20M$22.80M$25.20M$25.70M$26.50M
Intangibles$70.80M$103.40M$134.50M$173.30M$31.50M
Total assets$6.34B$6.48B$6.26B$5.39B$4.93B
Current liabilities$2.14B$2.93B$1.56B$1.84B$720.80M
Total liabilities$3.59B$4.38B$4.20B$3.26B$2.89B
Shareholders' equity$2.75B$2.10B$2.07B$2.13B$2.04B
Shares outstanding384.80M390.70M385.40M386.30M388.00M
Cash flow statement
Operating cash flow$1.44B$989.50M$748.50M$669.50M$442.50M
Capital expenditure$363.50M$358.80M$236.60M$364.80M$389.20M
Free cash flow$1.08B$630.70M$511.90M$304.70M$53.30M
Investing cash flow$536.00M-$207.50M-$507.20M-$521.50M-$216.10M
Financing cash flow-$1.69B-$734.80M-$318.60M-$552.50M$10.40M
Depreciation & amortization$251.80M$217.70M$186.00M$155.90M$102.00M
Stock-based compensation$159.60M$170.40M$150.80M$126.50M$113.40M
Share buybacks$500.00M$750.00M$688.70M$557.70M$0

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.